- Policy
- Forxiga generics continue being released in the Korean mkt
- by Lee, Tak-Sun Dec 20, 2023 05:40am
- Generic versions of Forxiga’s salt-modified drug, which were released in April, will be reimbursed from next month. These generics were released later than other Forxiga generics because the original salt-modified drug obtained first generic exclusivity in Korea, banning the sales of other salt-modified drugs that contain the same ingre
- InterView
- Targeted cardiomyopathy drug, Camzyos effective in Asians
- by Son, Hyung-Min Dec 19, 2023 11:19am
- The first targeted treatment option for obstructive hypertrophic cardiomyopathy has finally emerged. Obstructive hypertrophic cardiomyopathy (oHCM) is a sub-classification of hypertrophic cardiomyopathy that is characterized by LV outflow tract (LVOT) obstruction impeding blood flow from the heart to the rest of the body. Previously, t
- Company
- LG Chem joins in the 3-way race in Humira biosimilar mkt
- by Chon, Seung-Hyun Dec 19, 2023 05:54am
- LG Chem has joined in to compete for a share of the Humira biosimilar market. Humira is an original autoimmune disease treatment. With the introduction, a three-way competition will start between Samsung Bioepis, Celltrion, and LG Chem in the KRW 100 billion annual market. It has been 2 years since biosimilars entered the Humira market, but the
- Company
- 2 new JAK inhibitors secure expanded reimb
- by Son, Hyung-Min Dec 19, 2023 05:54am
- The treatment market for active ankylosing spondylitis, which had been previously dominated by Tumor Necrosis Factor-alpha (TNF-α) inhibitors such as Humira and Remicade, is transforming. As of the 1st of this month, reimbursement has been applied and expanded to include major Janus Kinase (JAK) inhibitors and biologic agents for treating activ
- Company
- Baxter-JW-HK Inno.N-Kabi introduce 4th gen 3 chamber TPNs
- by Nho, Byung Chul Dec 19, 2023 05:53am
- The race to expand the market share of ‘new lipid formulation total parenteral nutrition’ has been ignited by pharmaceutical companies specializing in parenteral nutrition. The new intravenous lipid total parenteral nutritions that have been introduced to the market are regarded as 4th generation total parenteral nutritions and are an
- Policy
- New drugs Zeposia, Koselugo, Trimbow are reimbursed
- by Lee, Tak-Sun Dec 19, 2023 05:53am
- New drugs including Zeposia Cap, Koselugo Cap, and Trimbow Cap will be listed for reimbursement starting January next year. In addition, Dong-A ST's diabetes combination drug ‘Sugatree XR Tab’ will also be reimbursed, and the reimbursement standards for drugs that have undergone reevaluation of their reimbursement adequacy will be adjus
- Company
- Who will take over the Forxiga market worth 50 bil?
- by Chon, Seung-Hyun Dec 18, 2023 05:31am
- The pharmaceutical industry is closely monitoring the potential withdrawal of the diabetes drug Forxiga from the market in Korea. This withdrawal is expected to intensify competition among companies aiming to fill the market gap left by Forxiga. Companies that have recently introduced generics of Forxiga are predicted to enter intense market com
- Company
- Dupixent seeks to expand its indication to COPD
- by Eo, Yun-Ho Dec 18, 2023 05:31am
- Indications for the interleukin inhibitor ‘Dupixent’ is being expanded actively in the field. According to industry sources, after being approved for rashes, Sanofi’s Dupixent (dupilumab) has further demonstrated efficacy in chronic obstructive pulmonary disease (COPD) and is seeking to expand its indication to the area. Its indica
- Policy
- PVA price cut rate will be raised by up to 15%
- by Lee, Tak-Sun Dec 18, 2023 05:31am
- From next year, items with higher insurance claims will be subject to higher price cuts when negotiating prices through the Price-Volume Agreement (PVA) system. The maximum price cut rate is also expected to be raised to 15% from the current 10%. However, the exclusion limit will also be raised to KRW 3 billion from the current 2 billion
- Opinion
- [Reporter’s view] On improving self-sufficiency of APIs
- by Kim, Jin-Gu Dec 18, 2023 05:31am
- The government said it has planned to lower reliance on imports of cutting-edge parts and raw materials from foreign countries to below 50%. The Ministry of Trade, Industry, and Energy (MOTIE) recently announced a ‘3050 strategy for the industry supply chain,’ which aims to lower the reliance on imports from any single foreign country f
